Study led by St. Jude Children’s Research Hospital finds an inherited gene variation—more common among Hispanic Americans–is tied to increased risk of developing a high-risk form of pediatric leukemia
Research led by St. Jude Children’s Research Hospital scientists has linked an inherited gene variation to a nearly four-fold increased risk of developing a pediatric acute lymphoblastic leukemia (ALL) subtype that is associated with a poor outcome. The study appears today in the online edition of the scientific journal Nature Genetics.
The high-risk variant was found in the GATA3 gene. Researchers reported the high-risk version of the gene was more common among Hispanic Americans and other individuals with at least 10 percent Native American ancestry than those of other ethnic backgrounds. Forty percent of Hispanic Americans carried the high-risk variant, compared to 14 percent of individuals of European ancestry. For this study, ethnicity was defined by genetic variations associated with ancestry rather than individual self-reports.
Hispanic children are known to be at a higher risk of developing ALL and of dying from the disease. This is the latest in a series of St. Jude studies to report an association between inherited DNA variations and an increased risk of childhood ALL among those of Hispanic ethnicity.
This is the first study to link an inherited genetic variation to an elevated risk of developing the leukemia subtype known as Philadelphia chromosome-like ALL (Ph-like ALL). Individuals with the high-risk version of GATA3 were 3.85 times more likely than those who inherited a different version of the gene to develop Ph-like ALL. Patients with the high-risk variant were also more likely to have a poor treatment response and have their cancer eventually return.
A significant percentage of patients with the high-risk GATA3 variant also had the tumor genetic alterations—including mutations, gene deletions and chromosomal re-arrangements—that are hallmark of Ph-like ALL. The changes occur in genes, including CRLF2, JAK and IKZF1 that regulate how blood cells grow and mature.
“Until recently, little was known about why a child develops a specific subtype of ALL in the first place and whether inherited genetic variations that predispose an individual to a subtype also influence how he or she responds to the therapy,” said corresponding author Jun J. Yang, Ph.D., an assistant member of the St. Jude Department of Pharmaceutical Sciences. “In this study, we discovered a genetic basis for susceptibility to Ph-like ALL, but even more importantly, the evidence that host and tumor genomes may interact with each other to influence the risk of developing and surviving ALL.”
The study was done in collaboration with the Children’s Oncology Group, a U.S.-based research cooperative study group focused on childhood cancer research and clinical trials. The research included 680 patients enrolled in COG clinical trials.
Ph-like ALL accounts for as much as 15 percent of childhood ALL and is associated with a high risk of relapse and a poor outcome. ALL is the most common childhood cancer. While overall cure rates for pediatric ALL are now about 90 percent, only 63 percent of children with Ph-like ALL are alive and cancer free after five years. Yang added that larger population studies are needed to assess risks associated with these inherited variations.
GATA3 carries instructions for assembling a protein called a transcription factor that turns other genes on and off. The GATA3 protein, and other members of the GATA gene family, plays a crucial role in normal development of a variety of blood cells. Alterations in GATA3 have been linked to other blood cancers, including Hodgkin lymphoma.
The high-risk GATA3 variation was identified using a library of 718,890 common genetic variations known as single nucleotide polymorphisms, or SNPs, to screen the DNA of 75 children with Ph-like ALL, 436 children with other ALL subtypes and 6,661 individuals without ALL. Fifty-eight percent of patients with Ph-like ALL carried the high-risk version of the gene, compared to 29 percent of patients with other ALL subtypes and 20 percent of those without ALL. When researchers checked for the high-risk variant in additional patients with the Ph-like ALL subtype as well as other young ALL patients and individuals without the disease, they found the similar percentages carried the high-risk version.
Researchers found evidence the high-risk version of the gene was associated with significantly increased production of the GATA3 protein in cells growing in the laboratory. Investigators also found evidence that excess GATA3 activity in leukemia cells led to changes in the activity of other genes that mirrored Ph-like ALL. “Because this variant causes higher expression of GATA3in normal blood cells, we suspect that this increased level of GATA3 may set the stage for developing Ph-like ALL later,” said first author Virginia Perez-Andreu, M.D., Ph.D., a St. Jude postdoctoral fellow in the pharmaceutical sciences department.
The other authors are Kathryn Roberts, Wenjian Yang, Cheng Cheng, Deqing Pei, Heng Xu, Shuyu E, Yiping Fan, Colton Smith, Geoffrey Neale, Deepa Bhojwani, Ching-Hon Pui, William Evans, Mary Relling and Charles Mullighan, all of St. Jude; Joshua Yew-Suang Lim, formerly of St. Jude; Richard Harvey, I-Ming Chen and Cheryl Willman, all of University of New Mexico, Albuquerque; Julie Gastier-Foster, Nationwide Children’s Hospital, Columbus, Ohio; Meenakshi Devidas, University of Florida, Gainesville; Michael Borowitz, Johns Hopkins Medical Institute, Baltimore, Md.; Esteban Burchard, Dara Torgerson and Mignon Loh, all of University of California at San Francisco; Federico Antillon Klussmann and Cesar Rolando Najera Villagran, both of Unidad Nacional de Oncologia Pediatrica, Guatemala; Naomi Winick, University of Texas Southwestern Medical Center, Dallas; Bruce Camitta, Medical College of Wisconsin, Milwaukee; Elizabeth Raetz and William Carroll, New York University Cancer Institute; Brent Wood, University of Washington, Seattle; Feng Yue, Pennsylvania State University, State College, Pa.; Eric Larsen, Maine Children’s Cancer Program, Scarborough; W. Paul Bowman, Cook Children’s Medical Center, Ft. Worth, Texas; Michael Dean, National Cancer Institute; and Stephen Hunger, Children’s Hospital Colorado, University of Colorado, Aurora.
The research is supported in part by grants (CA156449, CA21765, CA36401, CA9854, CA114766, CA98413, CA140729 and GM92666) from the National Institutes of Health, the National Cancer Institute intramural program and ALSAC. Perez-Andreu is supported by a Spanish Ministry of Education Fellowship Grant and by St. Jude Children’s Research Hospital Academic Programs Special Fellowship. Yang is supported by the American Society of Hematology Scholar Award, Alex’s Lemonade Stand Foundation for Childhood Cancer Young Investigator Grant and by the Order of St. Francis Foundation. Roberts is supported by the Australian National Health and Medical Research Council Oversees Training Fellowship and a Haematology Society of Australia and New Zealand Novartis New Investigator Scholarship. Mullighan is a Pew Scholar in Biomedical Sciences and a St. Baldrick’s Scholar.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 50 years ago. St. Jude shares the discoveries it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.